Adma Biologics Outperforms Medical Sector This Year: A Comprehensive Analysis

Adma Biologics (ADMA) is a Medical stock that has outperformed the sector this year with a 6.8% year-to-date return. The company has a Zacks Rank of #2 (Buy) and a sector rank of #3. Cronos Group (CRON) is another Medical stock that has outperformed the sector with a 20.8% year-to-date return and a Zacks Rank of #1 (Strong Buy). Both stocks have positive earnings outlooks, with ADMA's full-year earnings estimate increasing 1.6% over the past 90 days.